Basic Information
| LncRNA/CircRNA Name | XLOC_009190 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | RNA-seq |
| Sample | tumor and paired normal samples |
| Expression Pattern | up-regulated |
| Function Description | the novel lncRNA XLOC_009190 affected the patients with lung adenocarcinoma by two possible pathways. It might act on MGST1 that protected cells by conjugation and glutathione peroxidase functions.four known lncRNAs, as well as one novel lncRNAs (XLOC_009190), which were differentially expressed between tumor and normal. |
| Pubmed ID | 31908488 |
| Year | 2019 |
| Title | RNA-Seq Analysis Identified XLOC_009190 as Potential Therapeutic Target for Lung Adenocarcinoma |
External Links
| Links for XLOC_009190 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |